Clinical Trial Update: Tolerance Study of the Dietary Supplement Lipidrive (ECPH1-03) [Phase 1, Phase 2]

View source ↗

Summary

Update on a Phase 1/2 tolerance study of the dietary supplement Lipidrive (ECPH1-03) conducted by Valbiotis in individuals with obesity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Lipiddrive

Snippet

Sponsor: Valbiotis | Conditions: Obese | Phase 1, Phase 2 | Status: COMPLETED